Two-hundred and eighty patients were included in this study. The median age was 63.5 (53.5 – 74.0) years, 34% of patients were >70 years, 78% were males, 92% Caucasian, 3% were active smokers, 74% were overweight, and 66% had at least one comorbidity (including diabetes (18%), hypertension (45%), and any cardiovascular (29%), neoplastic (15%), respiratory (9%), neurological (7%), renal (4%), liver (2%), and rheumatic (2%) disease). At hospital admission, COVID-19 associated symptoms had been present for 7 days (4 – 10), while 36.8% and 13.6% of patients had a PaO2/FiO2 ≤ 200 mmHg or ≤ 100 mmHg, respectively. Serum levels of C-reactive Protein (CRP), lactate dehydrogenase (LDH) and ferritin were 70.9 (28.2 – 121.6) mg/L, 340 (275 – 449) U/L, and 1068 (561 – 1876) ng/mL, respectively; plasma D-dimer levels were 1.01 (0.59 – 2.05) µg/mL, total lymphocytes were 1.0 (0.8 – 1.3) 109/L, and the neutrophils/lymphocytes ratio was 5.0 (3.1 – 8.6).
During hospitalization, 12 (4.3%) patients died, 24 (8.6%) were admitted to the intensive care unit (ICU), and 95 (34%) required mechanical ventilation (invasive or non-invasive). Antiretrovirals, hydroxychloroquine, and biological agents were administered to 222 (79%), 261 (93%), and 97 (35%) patients, respectively.
Fifty-nine (21.1%) patients were treated with steroids, after a median of 1 day (0 – 2) since admission, and for a total of 9 (7 – 16) days. Initially, intravenous methylprednisolone was used in 55 (93.2%) cases, oral prednisone in 3 (5.1%) cases, and intravenous dexamethasone in 1 (1.7%) case of steroid use. Initial steroid methylprednisolone-equivalent dosage was 0.87 (0-51 – 1.0) mg/Kg.
At steroid discontinuation, 44 (74.6%) steroid users were treated with intravenous methylprednisolone, 10 (6.9%) with oral prednisone, and 5 (8.5%) with intravenous dexamethasone; methylprednisolone-equivalent dosage was 0.38 (0.21 – 0.53) mg/Kg.
Differences between steroid users and non-users were observed with regard to the proportion of patients with a baseline PaO2/FiO2 ≤ 200 mmHg (45.8% vs 34.4% in steroids and non-steroids users, respectively; p=0.023) and ≤100 mmHg (16.9% vs 12.7%, p=0.027), and with regard to the length of hospitalization (20 vs 14 days; p<0.001). Although steroid users had a higher proportion of severe respiratory impairment at admission than non-users, no significant differences between the two groups were found with regard to mortality (6.8% vs 3.6%; p=0.29), use of mechanical ventilation (36% vs 34%; p=0.76), and risk of subsequent infections (10.4% in both groups; p=0.87). Among 47/59 steroid users without a previous diabetes mellitus diagnosis, 2 (4.3%) steroid users developed new-onset diabetes during hospitalization.
During follow-up, each patient underwent 4 (3 – 5) consecutive nasopharyngeal swabs. The distribution of follow-up nasopharyngeal swabs, and the proportion of negative samples according to days since first positive swab and use of steroids are reported in Figure 1. Time to negativization of nasopharyngeal swabs according to the use of steroids, biological agents, and baseline lymphocyte cell count is also shown in Figure 1.
Using multivariate analysis (Table 1), SARS-CoV-2 clearance was associated with age ≤70 years (aHR=1.52, CI 1.08 – 2.14; p=0.017), shorter symptoms duration at hospital admission (aHR=0.82 (0.70-0.96) per 5-days longer; p=0.015), baseline PaO2/FiO2 > 200 mmHg (aHR=1.44, CI 1.03 – 2.01; p=0.03), and a lymphocyte count at admission > 1.0*109/L (aHR=1.63, CI 1.16 – 2.28; p=0.005). Use of corticosteroids did not impact on viral clearance (aHR= 1.06, CI 0.73 – 1.55; p=0.755).
Table 1. Multivariable analysis: factors associated with the risk of negativization of nasopharyngeal swab.
Covariates
|
Category
|
Adjusted hazard ratio
(95% confidence interval)
|
p-value
|
Age, years
|
≤70 vs >70
|
1.517 (1.077-2.136)
|
0.017
|
Gender
|
Female vs Male
|
1.234 (0.847-1.800)
|
0.274
|
Days from symptoms to hospital admission
|
Per 5-days longer
|
0.821 (0.700-0.963)
|
0.015
|
Comorbidities*
|
≥1 vs none
|
1.070 (0.766-1.496)
|
0.691
|
PaO2/FiO2
|
>200 vs ≤200
|
1.440 (1.034-2.005)
|
0.031
|
Use of immunomodulatory drugs
|
Yes vs No
|
0.865 (0.624-1.199)
|
0.383
|
Use of antiviral drugs or hydroxychloroquine
|
Yes vs No
|
0.751 (0.296-1.904)
|
0.546
|
Use of steroid
|
Yes vs No
|
1.062 (0.728-1.548)
|
0.755
|
Lactate dehydrogenase, U/L
|
≤330 vs >330
|
0.915 (0.652-1.285)
|
0.608
|
C-reactive protein, mg/L
|
≤68.7 vs >68.7
|
0.888 (0.639-1.234)
|
0.478
|
Total lymphocytes, per 109/L
|
>1 vs ≤1
|
1.625 (1.156-2.284)
|
0.005
|
All covariates were measured at baseline.
*The following comorbidities were considered: malignancies, diabetes, cardiovascular disease, hypertension, asthma, chronic obstructive pulmonary disease, moderate or severe liver disease, moderate or severe renal disease, neurological disease (chronic neurological disorder, dementia), rheumatic diseases.